Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cephalon, Inc.
A court case claims that St. Jude Medical’s handling of implant battery issues several years ago defrauded insurers.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
“The spin-off will establish two separate companies, a fully integrated, pure play, eye health company built on the iconic Bausch Health brand and a long history of innovation, and an international diversified pharmaceutical company with leading physicians in gastroenterology, dermatology, aesthetics, neurology and an international pharma business,” says CEO Joseph Papa.
The company formerly known as Valeant, put together by a series of mergers, is ready to spin out the legacy Bausch + Lomb eyecare business that it used in its rebranding.
- Other Names / Subsidiaries
- Arana Therapeutics (Peptech and EvoGenix)
- BioAssets Development Corporation
- Ception Therapeutics
- ChemGenex Pharmaceuticals Limited
- CIMA Labs
- Gemin X Pharmaceuticals
- Zeneus Pharma